Pliant Therapeutics (PLRX) Receivables (2019 - 2024)

Pliant Therapeutics (PLRX) has 6 years of Receivables data on file, last reported at $2.3 million in Q4 2024.

• Receivables for Q4 2024 came in at $2.3 million, down 23.19% year-over-year; the trailing twelve-month figure through Dec 2024 was $2.3 million (down 23.19% YoY), and the FY2024 annual result was $2.3 million, changed N/A from the prior year.
• Receivables fell to $2.3 million in Q4 2024 per PLRX's latest filing, from $3.0 million in the prior quarter.
• Over five years, Receivables peaked at $9.3 million in Q4 2020 and troughed at $1.6 million in Q3 2021.
• A 5-year average of $3.9 million and a median of $3.0 million in 2022 frame the typical range for Receivables.
• The sharpest annual moves came in 2021 and 2022: Receivables slumped 77.42% in 2021, then soared 240.5% in 2022.
• A 5-year view of Receivables shows it stood at $9.3 million in 2020, then slumped by 74.32% to $2.4 million in 2021, then grew by 28.45% to $3.1 million in 2022, then dropped by 2.09% to $3.0 million in 2023, then declined by 23.19% to $2.3 million in 2024.
• Business Quant data shows PLRX's Receivables at $2.3 million in Q4 2024, $3.0 million in Q4 2023, and $2.0 million in Q3 2023.